Beutel Goodman & Co Ltd. Has $424.33 Million Position in Amdocs Limited $DOX

Beutel Goodman & Co Ltd. reduced its position in Amdocs Limited (NASDAQ:DOX) by 8.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,650,708 shares of the technology company’s stock after selling 405,100 shares during the period. Amdocs comprises about 2.4% of Beutel Goodman & Co Ltd.’s holdings, making the stock its 11th largest position. Beutel Goodman & Co Ltd. owned approximately 4.12% of Amdocs worth $424,330,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Quarry LP raised its holdings in Amdocs by 42.2% during the first quarter. Quarry LP now owns 391 shares of the technology company’s stock valued at $36,000 after buying an additional 116 shares in the last quarter. Rossby Financial LCC bought a new stake in Amdocs during the second quarter valued at about $41,000. SVB Wealth LLC acquired a new stake in shares of Amdocs in the first quarter valued at about $43,000. Caitong International Asset Management Co. Ltd increased its stake in shares of Amdocs by 537.8% in the second quarter. Caitong International Asset Management Co. Ltd now owns 472 shares of the technology company’s stock worth $43,000 after purchasing an additional 398 shares during the period. Finally, Neo Ivy Capital Management bought a new position in shares of Amdocs in the second quarter worth about $54,000. 92.02% of the stock is owned by institutional investors.

Amdocs Stock Performance

Shares of NASDAQ:DOX opened at $76.45 on Friday. The company has a current ratio of 1.17, a quick ratio of 1.22 and a debt-to-equity ratio of 0.23. Amdocs Limited has a 1-year low of $74.32 and a 1-year high of $95.41. The stock has a market capitalization of $8.63 billion, a P/E ratio of 15.14, a P/E/G ratio of 1.27 and a beta of 0.43. The business has a 50-day moving average price of $80.68 and a two-hundred day moving average price of $85.87.

Amdocs (NASDAQ:DOX) last issued its earnings results on Tuesday, November 11th. The technology company reported $1.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.82 by $0.01. The company had revenue of $1.15 billion for the quarter, compared to analyst estimates of $1.15 billion. Amdocs had a net margin of 12.46% and a return on equity of 19.78%. The company’s revenue for the quarter was down 9.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.70 EPS. Amdocs has set its FY 2026 guidance at 7.270-7.550 EPS and its Q1 2026 guidance at 1.730-1.790 EPS. Equities analysts predict that Amdocs Limited will post 6.21 earnings per share for the current year.

Amdocs Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Wednesday, December 31st will be issued a $0.527 dividend. This represents a $2.11 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Wednesday, December 31st. Amdocs’s dividend payout ratio is currently 41.78%.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Stifel Nicolaus decreased their price target on shares of Amdocs from $100.00 to $97.00 and set a “buy” rating on the stock in a research report on Wednesday, November 12th. Bank of America lowered their price objective on Amdocs from $100.00 to $97.00 and set a “buy” rating on the stock in a research note on Wednesday, November 12th. Wolfe Research restated a “peer perform” rating on shares of Amdocs in a research report on Thursday, November 13th. Wall Street Zen lowered Amdocs from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amdocs in a report on Thursday, October 30th. Two research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, Amdocs presently has an average rating of “Moderate Buy” and a consensus target price of $97.00.

Amdocs Company Profile

Amdocs Limited, through its subsidiaries, provides software and services worldwide. It designs, develops, operates, implements, supports, and markets open and modular cloud portfolio. The company provides CES23, a 5G and cloud-native microservices-based market-leading customer experience suite, that enables service providers to build, deliver, and monetize advanced services; Amdocs Subscription Marketplace, a software-as-a-service-based platform that includes an expansive network of pre-integrated digital services, such as media, gaming, eLearning, sports, and retail to security and business services; the monetization suite for charging, billing, policy, and revenue management; Intelligent networking suite with a set of modular, flexible, and open service lifecycle management capabilities for network automation journeys; amAIz, a telco GenAI framework; Amdocs Digital Brands Suite, a pre-integrated digital business suite; and Amdocs eSIM Cloud for service providers.